3,833 results match your criteria arbs


Structural insights into ligand recognition and activation of angiotensin receptors.

Trends Pharmacol Sci 2021 May 10. Epub 2021 May 10.

Research Center for Molecular Mechanisms of Aging and Age-Related Diseases, Moscow Institute of Physics and Technology, Dolgoprudny, Moscow Region, Russia; Bridge Institute, Departments of Chemistry and Biological Sciences, University of Southern California, Los Angeles, CA, USA. Electronic address:

G protein-coupled angiotensin II receptors, ATR and ATR, are integral components of the renin-angiotensin system (RAS) that regulates blood pressure and fluid balance in humans. While ATR is a well-established target of angiotensin receptor blockers (ARBs) for managing hypertension and a prime system for studying biased signaling, ATR has been recognized as a promising target against neuropathic pain and lung fibrosis. In this review, we discuss how recent structural advances illuminate ligand-binding modes and subtype selectivity, shared and distinct features of the receptors, their transducer-coupling patterns, and downstream signaling responses. Read More

View Article and Full-Text PDF

Associations Between the Use of Renin-Angiotensin System Inhibitors and the Risks of Severe COVID-19 and Mortality in COVID-19 Patients With Hypertension: A Meta-Analysis of Observational Studies.

Front Cardiovasc Med 2021 26;8:609857. Epub 2021 Apr 26.

Peking University People's Hospital, Beijing, China.

Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) share a target receptor with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The use of ACEIs/ARBs may cause angiotensin-converting enzyme 2 receptor upregulation, facilitating the entry of SARS-CoV-2 into host cells. There is concern that the use of ACEIs/ARBs could increase the risks of severe COVID-19 and mortality. Read More

View Article and Full-Text PDF

Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: a retrospective cohort study.

BMC Med 2021 05 12;19(1):118. Epub 2021 May 12.

Department of Cardiology, University Hospital Príncipe de Asturias, Alcalá de Henares, Madrid, Spain.

Background: In the first wave of the COVID-19 pandemic, the hypothesis that angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) increased the risk and/or severity of the disease was widely spread. Consequently, in many hospitals, these drugs were discontinued as a "precautionary measure". We aimed to assess whether the in-hospital discontinuation of ARBs or ACEIs, in real-life conditions, was associated with a reduced risk of death as compared to their continuation and also to compare head-to-head the continuation of ARBs with the continuation of ACEIs. Read More

View Article and Full-Text PDF

Randomized Prospective Open Label Study Shows No Impact on Clinical Outcome of Adding Losartan to Hospitalized COVID-19 Patients with Mild Hypoxemia.

Infect Dis Ther 2021 May 11. Epub 2021 May 11.

Sharp Memorial Hospital, Sharp Memorial Research Pharmacy, 7901 Frost Street, San Diego, CA, 92123, USA.

Introduction: Despite considerable scientific debate, there have been no prospective clinical studies on the effects of angiotensin II receptor blockers (ARBs) on the course of COVID-19 infection. Losartan is the ARB that was chosen to be tested in this study.

Methods: Patients with COVID-19 and mild hypoxia (receipt of ≤ 3 L/min O by nasal cannula) admitted to three hospitals were randomized in a 1:1 ratio within 72 h of SARS-CoV-2 nucleic acid testing confirmation to prospectively receive standard of care (SOC) alone or SOC plus losartan 12. Read More

View Article and Full-Text PDF

Angiotensin II Receptor Blockers but Not Angiotensin-Converting Enzyme Inhibitors Are Associated With a Reduced Risk of Acute Kidney Injury After Major Surgery.

Front Pharmacol 2021 23;12:662301. Epub 2021 Apr 23.

Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, Taipei, Taiwan.

We investigated the respective effects of preoperative angiotensin-converting-enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) on the incidence of postoperative acute kidney injury (AKI) and mortality. In this nested case-control study, we enrolled 20,276 patients who received major surgery. We collected their baseline demographic data, comorbidities and prescribed medication, the outcomes of postoperative AKI and mortality. Read More

View Article and Full-Text PDF

Intolerance to angiotensin converting enzyme inhibitors in asthma and the general population: a UK population-based cohort study.

J Allergy Clin Immunol Pract 2021 May 6. Epub 2021 May 6.

Division of Population Health and Genomics, University of Dundee, UK.

Background: Angiotensin converting enzyme inhibitor (ACEI) intolerance commonly occurs requiring switching to an angiotensin-II receptor blocker (ARB). ACEI intolerance may be mediated by bradykinin potentially affecting airway hyper-responsiveness.

Objective: Assess the risk of switching to ARBs in asthma. Read More

View Article and Full-Text PDF

Effect of medical treatment on heart failure incidence in patients with a systemic right ventricle.

Heart 2021 May 6. Epub 2021 May 6.

Adult Congenital Heart Centre, National Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, UK.

Background: To date, clinical trials have been underpowered to demonstrate a benefit from ACE inhibitors (ACEis) or angiotensin II receptor blockers (ARBs) in preventing systemic right ventricle (sRV) failure and disease progression in patients with transposition of the great arteries (TGA). This observational study aimed to estimate the effect of ACEi and ARB on heart failure (HF) incidence and mortality in a large population of patients with an sRV.

Methods: Data on all patients with an sRV under active follow-up at two tertiary centres between January 2007 and September 2018 were studied. Read More

View Article and Full-Text PDF

The effect of RAAS inhibitors on acute hypoxemic respiratory failure and in-hospital mortality in the hypertensive Covid-19 patients.

Clin Exp Hypertens 2021 May 6:1-10. Epub 2021 May 6.

Department of Cardiology, University of Health Sciences Diyarbakır Gazi Yaşargil Education and Research Hospital, Diyarbakır, Turkey.

Introduction: We have aimed to investigate the relationship between use of angiotensin-converting-enzyme inhibitor (ACEI) or angiotensin-receptor-blocker (ARB) drugs and acute hypoxemic respiratory failure (AHRF) and in-hospital mortality in hypertensive Covid-19 patients.

Material And Method: Consecutive 1345 patients diagnosed with Covid-19 between April and October 2020 who met inclusion criteria were divided into two groups based on presence and absence of AHRF and mortality. The groups were compared regarding epidemiological, clinical, radiological, laboratory findings and treatments methods. Read More

View Article and Full-Text PDF

The angiotensin II type 1 receptor blocker valsartan in the battle against COVID-19.

Obesity (Silver Spring) 2021 May 5. Epub 2021 May 5.

Department of Human Biology, Maastricht University Medical Center, NUTRIM School for Nutrition and Translational Research in Metabolism, The Netherlands.

Objective: SARS-CoV-2 uses the hosts angiotensin-converting enzyme 2 (ACE2) as cellular entry point. Hence, modulating ACE2 might impact SARS-CoV-2 viral replication, shedding and COVID-19 severity. Here, we investigated if the angiotensin II type 1 receptor (AT1R) blocker valsartan alters the expression of renin-angiotensin system (RAS) components, including ACE2, in human adipose tissue (AT) and skeletal muscle. Read More

View Article and Full-Text PDF

Drug Intake and Actinic Keratosis: A Case-Control Study.

Dermatol Pract Concept 2021 Mar 12;11(2):e2021031. Epub 2021 Apr 12.

Dermatology, IRCCS Policlinico di Sant'Orsola. Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum University of Bologna, Italy.

Background: Actinic keratosis (AK) is a form of premalignant keratinocyte dysplasia. Recently, the role of photosensitizing drugs in the development of AK has been postulated.

Objective: This study evaluated a possible association between the use of photosensitizing drugs and the development of AK. Read More

View Article and Full-Text PDF

Epidemiology, Clinical Characteristics, and Outcomes of a Large Cohort of COVID-19 Outpatients in Michigan.

Int J Gen Med 2021 28;14:1555-1563. Epub 2021 Apr 28.

Internal Medicine Department, Beaumont Health, Royal Oak, MI, USA.

Background: Most outpatients with coronavirus disease 2019 (COVID-19) do not initially demonstrate severe features requiring hospitalization. Understanding this population's epidemiological and clinical characteristics to allow outcome anticipation is crucial in healthcare resource allocation.

Methods: Retrospective, multicenter (8 hospitals) study reporting on 821 patients diagnosed with COVID-19 by real-time reverse transcriptase-polymerase chain reaction assay of nasopharyngeal swabs and discharged home to self-isolate after evaluation in emergency departments (EDs) within Beaumont Health System in March, 2020. Read More

View Article and Full-Text PDF

Barriers to ACEI/ARB Use in Proteinuric Chronic Kidney Disease: An Observational Study.

Mayo Clin Proc 2021 May 2. Epub 2021 May 2.

Division of Nephrology, Stanford University School of Medicine, Palo Alto, CA.

Objective: To assess present angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) use among patients with proteinuric chronic kidney disease (CKD) and examine barriers limiting this guideline-concordant care.

Patients And Methods: Using a nationwide database containing patient-level claims and integrated clinical information, we examined current ACEI/ARB prescriptions on the index date (April 15, 2017) and prior ACEI/ARB use in 41,743 insured adults with proteinuric CKD. Using multivariable logistic regression, we estimated adjusted associations between current ACEI/ARB use and putative barriers including past acute kidney injury (AKI), hyperkalemia, advanced CKD, and lack of nephrology care. Read More

View Article and Full-Text PDF

Efficacy and Safety of LCZ696 for Short-term Management of Essential Hypertension Compared With ARBs: A Meta-analysis of Randomized Controlled Trials.

J Cardiovasc Pharmacol 2021 May;77(5):650-659

Department of Cardiovascular Medicine, Second Affiliated Hospital of Nanchang University, Nanchang, China; and.

Abstract: Whether LCZ696 (neprilysin inhibitor + valsartan) has greater advantages of blood pressure (BP) lowering than angiotensin II type 1 receptor blockers (ARBs) is unclear. To provide more detailed information about the benefits of LCZ696, we conducted a meta-analysis to evaluate the efficacy and safety of LCZ696 for short-term management of hypertension compared with ARBs. We searched PubMed, EMBASE, the Cochrane Library, and ClinicalTrials. Read More

View Article and Full-Text PDF

Inhibition of the renin-angiotensin-aldosterone system prevents and cures atrial fibrillation: An overview of systematic reviews.

Medicine (Baltimore) 2021 May;100(18):e25559

Department of Cardiology, Xijing Hospital, The Air Force Military Medical University, Xi'an Shaanxi, China.

Abstract: Background: Atrial fibrillation (AF) is a type of arrhythmia that represents a severe health hazard. The current therapies for AF have achieved success in some conditions. However, because the mechanisms underlying the occurrence and development of this disease remain unclear, the current treatment for AF often does not achieve the desired outcomes. Read More

View Article and Full-Text PDF

Using an Information Package to Reduce Patients' Risk of Renal Damage: Protocol for a Randomized Feasibility Trial.

JMIR Res Protoc 2021 Apr 30;10(4):e29161. Epub 2021 Apr 30.

Department of General Practice and Rural Health, Otago Medical School - Dunedin Campus, University of Otago, Dunedin, New Zealand.

Background: Non-steroidal anti-inflammatory drugs (NSAIDs) are a common cause of renal damage, especially when taken together with angiotensin-converting enzyme inhibitors (ACE-i) or angiotensin II receptor blockers (ARBs) plus a diuretic - a combination known as the "triple whammy." New Zealand patients are at high risk of the "triple whammy" because they can easily purchase NSAIDs without a prescription and in nonpharmacy retail settings (eg, the supermarket), there is no legal requirement to include patient information sheets with medication, and direct-to-consumer drug advertising is permitted. A patient information package has been developed for those at greatest risk of the "triple whammy," consisting of a printable PDF and an interactive online learning activity. Read More

View Article and Full-Text PDF

Effects of SARS-CoV-2 on Cardiovascular System: The Dual Role of Angiotensin-Converting Enzyme 2 (ACE2) as the Virus Receptor and Homeostasis Regulator-Review.

Int J Mol Sci 2021 Apr 26;22(9). Epub 2021 Apr 26.

Cardiothoracovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI) and Department of Medical Surgical and Health Science, University of Trieste, 34149 Trieste, Italy.

Angiotensin-converting enzyme 2 (ACE2) is the entry receptor for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the cause of Coronavirus Disease-2019 (COVID-19) in humans. ACE-2 is a type I transmembrane metallocarboxypeptidase expressed in vascular endothelial cells, alveolar type 2 lung epithelial cells, renal tubular epithelium, Leydig cells in testes and gastrointestinal tract. ACE2 mediates the interaction between host cells and SARS-CoV-2 spike (S) protein. Read More

View Article and Full-Text PDF

Prevalence of Antibiotic-Resistant Bacteria ESKAPE among Healthy People Estimated by Monitoring of Municipal Wastewater.

Antibiotics (Basel) 2021 Apr 26;10(5). Epub 2021 Apr 26.

Department of Food, Life and Environmental Sciences, Faculty of Agriculture, Yamagata University, Tsuruoka 9978555, Japan.

There is increasing attention toward factors that potentially contribute to antibiotic resistance (AR), as well as an interest in exploring the emergence and occurrence of antibiotic resistance bacteria (ARB). We monitored six ARBs that cause hospital outbreaks in wastewater influent to highlight the presence of these ARBs in the general population. We analyzed wastewater samples from a municipal wastewater treatment plant (MWWTP) and hospital wastewater (HW) for six species of ARB: Carbapenem-resistant Enterobacteria (CARBA), extended-spectrum β-lactamase producing Enterobacteria (ESBL), multidrug-resistant Acinetobacter (MDRA), multidrug-resistant (MDRP), methicillin-resistant (MRSA), and vancomycin-resistant Enterococci (VRE). Read More

View Article and Full-Text PDF

Beneficial Effect of Left Ventricular Remodeling after Early Change of Sacubitril/Valsartan in Patients with Nonischemic Dilated Cardiomyopathy.

Medicina (Kaunas) 2021 Apr 25;57(5). Epub 2021 Apr 25.

Division of Cardiology, Heart Stroke Vascular Center, Incheon Sejong Hospital, 20, Gyeyangmunhwa-ro, Gyeyang-gu, Incheon 21080, Korea.

Evidence for effectiveness of early change from angiotensin II receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors (ACEIs) to sacubitril/valsartan is lacking. We aimed to investigate whether early changes to sacubitril/valsartan could improve outcomes in patients with nonischemic dilated cardiomyopathy (DCM) in real-world practice. : A total of 296 patients with nonischemic DCM who were treated with ARB or ACEI continuously (group A, = 150) or had their medication switched to sacubitril/valsartan (group S, = 146) were included. Read More

View Article and Full-Text PDF

Antihypertensive medications and COVID-19 diagnosis and mortality: Population-based case-control analysis in the United Kingdom.

Br J Clin Pharmacol 2021 Apr 27. Epub 2021 Apr 27.

King's College London, School of Population Health and Environmental Sciences, London, UK.

Aims: Antihypertensive drugs have been implicated in coronavirus disease 2019 (COVID-19) susceptibility and severity, but estimated associations may be susceptible to bias. We aimed to evaluate antihypertensive medications and COVID-19 diagnosis and mortality, accounting for healthcare-seeking behaviour.

Methods: A population-based case-control study was conducted including 16 866 COVID-19 cases and 70 137 matched controls from the UK Clinical Practice Research Datalink. Read More

View Article and Full-Text PDF

Potential protective role of ACE-inhibitors and AT1 receptor blockers against levodopa-induced dyskinesias: a retrospective case-control study.

Neural Regen Res 2021 Dec;16(12):2475-2478

Movement Disorders Centre, Neurology Unit, Department of Translational Medicine, University of Piemonte Orientale, Novara; Center of Research in Medical Pharmacology, University of Insubria, Varese, Italy.

Growing evidence has highlighted that angiotensin-converting enzyme (ACE)-inhibitors (ACEi)/AT1 receptor blockers (ARBs) may influence the complex interplay between dopamine and the renin-angiotensin system in the nigrostriatal pathway, thus affecting the development of levodopa-induced dyskinesia in Parkinson's disease (PD). In the present study, we analyzed whether the use of this class of medication was associated with a reduced occurrence of levodopa-induced dyskinesia, using electronically-stored information of idiopathic PD patients enrolled at Novara University Hospital "Maggiore della Carità". We conducted a retrospective case-control study identifying PD patients with dyskinesias (PwD; n = 47) as cases. Read More

View Article and Full-Text PDF
December 2021

Expression of the SARS-CoV-2 receptorACE2 in human heart is associated with uncontrolled diabetes, obesity, and activation of the renin angiotensin system.

Cardiovasc Diabetol 2021 04 27;20(1):90. Epub 2021 Apr 27.

Cardiac Research Laboratory, Felsenstein Medical Research Center, Sackler School of Medicine Tel-Aviv University, Tel Aviv, Israel.

Background: Diabetic and obese patients are at higher risk of severe disease and cardiac injury in corona virus 2 (SARS-CoV-2) infections. Cellular entry of SARS-CoV-2 is mainly via the angiotensin-converting enzyme 2 (ACE2) receptor, which is highly expressed in normal hearts. There is a disagreement regarding the effect of factors such as obesity and diabetes on ACE2 expression in the human heart and whether treatment with renin-angiotensin system inhibitors or anti-diabetic medications increases ACE2 expression and subsequently the susceptibility to infection. Read More

View Article and Full-Text PDF

Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans.

PLoS One 2021 23;16(4):e0248080. Epub 2021 Apr 23.

Department of Population Health Sciences, Division of Health System Innovation and Research, University of Utah School of Medicine, Salt Lake City, UT, United States of America.

Background: Angiotensin II receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) may positively or negatively impact outcomes in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We investigated the association of ARB or ACEI use with coronavirus disease 2019 (COVID-19)-related outcomes in US Veterans with treated hypertension using an active comparator design, appropriate covariate adjustment, and negative control analyses.

Methods And Findings: In this retrospective cohort study of Veterans with treated hypertension in the Veterans Health Administration (01/19/2020-08/28/2020), we compared users of (A) ARB/ACEI vs. Read More

View Article and Full-Text PDF

Does taking an angiotensin inhibitor increase the risk for COVID-19? - a systematic review and meta-analysis.

Aging (Albany NY) 2021 04 22;13(8):10853-10865. Epub 2021 Apr 22.

Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Chaoyang 100020, Beijing, China.

Because SARS-COV2 entry into cells is dependent on angiotensin converting enzyme 2 (ACE2) and angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) increase ACE2 activity, the safety of ACEI/ARB usage during the coronavirus disease 2019 (COVID-19) pandemic is a controversial topic. To address that issue, we performed a meta-analysis following The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Searches of the Embase, MEDLINE, PubMed, and Cochrane Library databases identified 16 case-control studies examining the effect of ACEI/ARB on the incidence of COVID-19 and its severity. Read More

View Article and Full-Text PDF

Classical and Counter-regulatory Renin-angiotensin System: potential key roles in COVID-19 pathophysiology.

CJC Open 2021 Apr 15. Epub 2021 Apr 15.

King Abdullah International Medical Research Centre, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.

In the current coronavirus disease 2019 (COVID-19) pandemic, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses angiotensin-converting enzyme-2 (ACE-2) receptor for cell entry leading to ACE-2 dysfunction and downregulation which disturbs the balance between classical and counter-regulatory renin-angiotensin system (RAS) in favor of classical RAS. RAS dysregulation is one of the major characteristics of several cardiovascular diseases, thus adjustment of this system is the main therapeutic target. RAS inhibitors - particularly angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs) - are commonly used for treatment of hypertension and cardiovascular disease. Read More

View Article and Full-Text PDF

Acute Cardiac Injury in Coronavirus Disease 2019 and Other Viral Infections-A Systematic Review and Meta-Analysis.

Crit Care Med 2021 Apr 19. Epub 2021 Apr 19.

Department of Medicine, McGill University, Montreal, PQ, Canada. Department of Medicine, University of British Columbia, Vancouver, BC, Canada. Division of Pulmonary and Critical Care Medicine, Department of Medicine, New York Presbyterian Hospital, Columbia University, New York, NY. Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada. Department of Pediatrics, BC Children's Hospital, University of British Columbia, Vancouver, BC, Canada. Centre for Health Evaluation and Outcomes Science (CHEOS), University of British Columbia, Vancouver, BC, Canada. Department of Medicine, Centre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada. Department of Critical Care Medicine, Queen's University, Kingston, ON, Canada. Department of Medicine and Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, ON, Canada. Divisions of Internal Medicine and Infectious Diseases, Department of Medicine, Toronto General Hospital, University Health Network, Toronto, ON, Canada. Department of Medicine, Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada.

Objectives: Severe acute respiratory syndrome-related coronavirus-2 binds and inhibits angiotensin-converting enzyme-2. The frequency of acute cardiac injury in patients with coronavirus disease 2019 is unknown. The objective was to compare the rates of cardiac injury by angiotensin-converting enzyme-2-binding viruses from viruses that do not bind to angiotensin-converting enzyme-2. Read More

View Article and Full-Text PDF

The effects of ACE2 expression mediating pharmacotherapy in COVID-19 patients.

Neth Heart J 2021 May 16;29(Suppl 1):20-34. Epub 2021 Apr 16.

Department of Experimental Cardiology, Amsterdam University Medical Center, Amsterdam, The Netherlands.

Background: There has been debate on the use of angiotensin-converting enzyme‑2 (ACE2) expression mediating pharmacotherapy in COVID-19 infected patients. Although it has been suggested that these drugs might lead to a higher susceptibility and severity of COVID-19 infection, experimental data suggest these agents may reduce acute lung injury via blocking angiotensin-II-mediated pulmonary permeability, inflammation and fibrosis.

Methods: A systematic literature search was performed to answer the question: What is the effect of medications that influence ACE2 expression (ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), nonsteroidal anti-inflammatory drugs (NSAIDs) and thiazolidinediones) on the outcomes of COVID-19? Relevant outcome measures were mortality (crucial), hospital admission, length of stay, thromboembolic complications (pulmonary embolism, stroke, transient ischaemic attack), need for mechanical ventilation, acute kidney injury and use of renal replacement therapy. Read More

View Article and Full-Text PDF

Withholding vs. Continuing Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Before Non-cardiac Surgery in Older Patients: Study Protocol for a Multicenter Randomized Controlled Trial.

Front Med (Lausanne) 2021 30;8:654700. Epub 2021 Mar 30.

Department of Anesthesiology, First Affiliated Hospital of Soochow University, Suzhou, China.

Older hypertensive adults are at increased risk for postoperative morbidity and mortality. As first line antihypertensive drug therapy, angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) have many beneficial effects. However, the use of ACEIs/ARBs in the perioperative period remains controversial. Read More

View Article and Full-Text PDF

Different therapeutic associations of renin-angiotensin system inhibitors with coronavirus disease 2019 compared with usual pneumonia.

Korean J Intern Med 2021 Apr 16. Epub 2021 Apr 16.

Korean Society of Hypertension, Seoul, Korea.

Background/aims: Although it is near concluded that renin-angiotensin system inhibitors do not have a harmful effect on coronavirus disease 2019 (COVID-19), there is no report about whether angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) offer any protective role. This study aimed to compare the association of ARBs and ACEIs with COVID-19-related mortality.

Methods: All patients with COVID-19 in Korea between January 19 and April 16, 2020 were enrolled. Read More

View Article and Full-Text PDF